Theme 5. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 79-81

  Montroni, Maria ^a   D'Arminio Monforte, Antonella ^b   Butini, L ^a   Constantini, A ^a   Regnery, C M ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ARTICLE; CLINICAL PRACTICE; CROSS RESISTANCE; DISEASE COURSE; DRUG SENSITIVITY; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; SPECIES DIFFERENCE; STRAIN DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MICROBIOLOGICAL EXAMINATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE; VIRAL LOAD; VIRUS REPLICATION;

EID: 1242320996     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency infection. N Engl J Med 1998; 338: 853-60.
2. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-8.
3. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4 T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181: 946-53.
4. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-9.
5. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16: 209-18.
6. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13: F123-9.
7. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857-67.
8. Deeks SG, Wrin T, Liegler T, Hoh R. Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patient with detectable viremia. N Engl J Med 2001; 344: 472-80.
9. Miller V, Sabin C, Hertogs K, Martinez-Picaod J, D'Aquilla R, Larder B et al. Antiretroviral treatment interruption in patients with treatment failure: analysis from the Frankfurt HIV cohort. 3rd International Workshop on Salvage Therapy for HIV Infection, Chicago, USA, 12-14 April 2000 (Abstract 25). Antiviral Ther 2000; 5 (Suppl 2): 22.
10. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15: 2189-98.
11. Albrecht D, Zöllner B, Feucht H-H. Lorenzen T, Laufs R, Stoehr A, Plettemberg A. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol 2002; 24: 93-8.
12. Dorman KS, Kaplan AH, Lange K, Sinsheimer JS. Mutation takes no vacations: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J AIDS 2000; 25: 3.
13. DHHS. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 2002.
14. International AIDS Society-USA. Update of resistance mutations in HIV-1. Topics HIV Med 2001; 9: 21-27.
15. Izopet J, Massip P, Souyris C, Sandres K, Puissant B, Obadia M, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 2000; 14: 2247-55.
16. Lundgren JD, Vella S, Paddam L, Blaxhult A, Vetter N, Clumeck N, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA Study. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002. Abstract 48.